TL;DR
This study reveals that neurons from individuals with schizophrenia exhibit abnormal patterns of histone acetylation, specifically hyperacetylation of H2A.Z and H4. They identify the BET protein BRD4 as a key "reader" of this aberrant acetylation and demonstrate that inhibiting BET proteins can partially correct gene expression abnormalities in these neurons, suggesting a potential therapeutic avenue for schizophrenia.
What Problem Does This Paper Address?
Schizophrenia (SZ) is a complex psychiatric disorder with a strong genetic component, but understanding its underlying molecular mechanisms remains a significant challenge. While epigenetic factors like histone modifications are known to play crucial roles in neurodevelopment and disease, how they contribute to SZ is not fully understood. Previous research has largely focused on specific histone modifications using candidate-based approaches. This paper aims to provide a more comprehensive, unbiased view of histone modifications in SZ by investigating combinatorial histone PTMs in human neurons derived from individuals with the disorder.
Methods
The researchers employed a multi-pronged approach:
- Unbiased Histone PTM Mass Spectrometry (LC-MS/MS): This technique allowed for the simultaneous quantification of hundreds of histone PTMs, both individually and in combination, in human induced pluripotent stem cell (hiPSC)-derived neurons, neural progenitor cells (NPCs), and postmortem brain tissue from SZ cases and controls.
- Isothermal Titration Calorimetry (ITC): Used to precisely measure the binding affinities of the BET protein BRD4 (specifically its bromodomains) to various acetylated H2A.Z peptides.
- X-ray Crystallography: Determined the high-resolution crystal structure of the BRD4-bromo2 domain in complex with an acetylated H2A.Z peptide, providing atomic-level detail of their interaction.
- Mutagenesis Studies: Investigated the role of specific amino acid residues in the BRD4-H2A.Z interaction.
- Chromatin Immunoprecipitation Sequencing (ChIP-seq): Examined the genome-wide co-enrichment of acetylated H2A.Z and BRD4 at gene promoters in human cells.
- RNA Sequencing (RNA-seq): Analyzed global gene expression changes in SZ and control neurons, both with and without treatment with a BET inhibitor (JQ1).
- Weighted Gene Co-expression Network Analysis (WGCNA): Identified modules of co-expressed genes and their association with SZ and JQ1 treatment.
- Competitive Gene-Set Enrichment Analysis: Assessed the enrichment of specific gene sets in differential expression data.
Datasets
- Human Induced Pluripotent Stem Cell (hiPSC)-derived neurons, NPCs, and forebrain neurons: Derived from individuals with schizophrenia (SZ) and matched controls.
- Postmortem human brain tissue: Specifically, dorsolateral prefrontal cortex (DLPFC) from SZ cases and matched controls.
- HeLa cells: Used for ChIP-seq experiments.
- External dataset: Postmortem brain tissue data from the Common Mind Consortium (CMC) was used for concordance analysis.
Key Insights and Ideas
- Aberrant Histone Acetylation in SZ Neurons: The most striking finding is the observation of combinatorial hyperacetylation on H2A.Z and H4 in neurons from individuals with SZ, a pattern not seen in earlier developmental stages or in control neurons. This suggests a specific dysregulation occurring during neuronal maturation.
- BRD4 as a "Reader" of Aberrant H2A.Z Acetylation: The study provides strong evidence that BRD4, a key epigenetic "reader" protein, directly binds to acetylated H2A.Z. This interaction is crucial for understanding how the aberrant acetylation might translate into functional changes.
- BET Inhibitors as a Potential Therapeutic Strategy: The demonstration that inhibiting BET family proteins (like BRD4) with JQ1 can ameliorate transcriptional abnormalities in SZ neurons is a significant finding. This suggests that targeting these interactions could be a viable therapeutic approach for SZ.
- Structural Basis for Interaction: The crystal structure of BRD4-bromo2 bound to acetylated H2A.Z provides atomic-level insights into how this recognition occurs, highlighting specific amino acid interactions that are critical for binding.
Key Results
- Hyperacetylation of H2A.Z and H4: Significant increases in combinatorial acetylation of H2A.Z (specifically K4acK7acK11ac) and H4 were observed in SZ neurons compared to controls, confirmed in both hiPSC-derived neurons and postmortem brain tissue.
- BRD4 Binding Affinity: ITC experiments showed that BRD4 bromodomains bind to acetylated H2A.Z peptides with affinities comparable to known interactions, such as with H4 peptides.
- JQ1 Ameliorates Gene Expression: RNA-seq analysis revealed that treatment with the BET inhibitor JQ1 partially rescued gene expression deficits observed in SZ neurons, particularly for gene sets related to neurological disorders.
- Genome-wide Overlap: ChIP-seq data indicated a strong correlation between H2A.Z acetylation and BRD4 occupancy at gene promoters, suggesting a widespread functional interplay.
Limitations and Future Work
- Cellular Model Limitations: While hiPSC-derived neurons offer a valuable model, they do not fully recapitulate the complexity of the adult human brain.
- Translational Challenges: The study primarily uses in vitro models. Further research is needed to confirm these findings in vivo and to develop safe and effective BET inhibitors for clinical use in SZ.
- Specificity of BET Inhibitors: While JQ1 is a potent inhibitor, its broad action across BET family proteins might have off-target effects. Future work could explore more specific inhibitors.
- Mechanistic Elucidation: While the study identifies BRD4 as a reader, the precise downstream consequences of this interaction in the context of SZ neurodevelopment require further investigation.
- Therapeutic Potential: The authors suggest that BET inhibitors warrant further investigation as potential therapeutics for SZ, emphasizing the need for studies exploring their efficacy and safety in preclinical and clinical settings.
Summary updated